DOI:
10.1055/s-00034925
Hämostaseologie
LinksClose Window
References
Pharmacovigilance Risk Assessment Committee of the European Medicines Agency.
New product information wording: Direct-acting oral anticoagulants (DOACs): apixaban; dabigatran etexilate; edoxaban; rivaroxaban – Recurrent thrombosis in patients with antiphospholipid syndrome (EPITT no 19320).
Available at:
https://www.ema.europa.eu/en/documents/other/new-product-information-wording-extracts-prac-recommendations-signals-adopted-8-11-april-2019-prac_en.pdf 2019
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.